In preclinical studies, PARP inhibitors showed antitumor effects not only in ovarian cancers but also on uterine sarcoma cell lines with BRCA2 gene mutations (SK-UT-1 and SK-UT-1B) in a concentration-dependent manner [51]. This evidence concerns the gene BRCA2 and uterine corpus sarcoma.